BioXcel Therapeutics (NASDAQ:BTAI) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS

BioXcel Therapeutics (NASDAQ:BTAI) released its earnings results on Tuesday. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.02), Bloomberg Earnings reports.

BTAI stock traded down $0.84 during trading on Wednesday, reaching $8.01. 2,427 shares of the stock traded hands, compared to its average volume of 22,448. The firm’s 50 day simple moving average is $10.76. BioXcel Therapeutics has a 52-week low of $2.41 and a 52-week high of $12.00. The company has a quick ratio of 5.59, a current ratio of 5.59 and a debt-to-equity ratio of 0.04. The firm has a market cap of $138.68 million, a price-to-earnings ratio of -5.88 and a beta of 3.02.

BTAI has been the subject of several analyst reports. Zacks Investment Research lowered BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. HC Wainwright set a $25.00 price target on BioXcel Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 5th. Finally, ValuEngine downgraded BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 8th.

An institutional investor recently bought a new position in BioXcel Therapeutics stock. Creative Planning purchased a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned 0.20% of BioXcel Therapeutics at the end of the most recent quarter. 16.03% of the stock is owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: Call Option

Earnings History for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with's FREE daily email newsletter.